BACKGROUND: Metastatic biopsies are increasingly being performed in patients with advanced prostate cancer to search for actionable targets and/or to identify emerging resistance mechanisms. Due to a predominance of bone metastases and their sclerotic nature, obtaining sufficient tissue for clinical and genomic studies is challenging. METHODS: Patients with prostate cancer bone metastases were enrolled between February 2013 and March 2017 on an institutional review board-approved protocol for prospective image-guided bone biopsy. Bone biopsies and blood clots were collected fresh. Compact bone was subjected to formalin with a decalcifying agent for diagnosis; bone marrow and blood clots were frozen in optimum cutting temperature formulation for nextgeneration sequencing. Frozen slides were cut from optimum cutting temperature cryomolds and evaluated for tumor histology and purity. Tissue was macrodissected for DNA and RNA extraction, and whole-exome sequencing and RNA sequencing were performed. RESULTS: Seventy bone biopsies from 64 patients were performed. Diagnostic material confirming prostate cancer was successful in 60 of 70 cases (85.7%). The median DNA/RNA yield was 25.5 ng/lL and 16.2 ng/lL, respectively. Whole-exome sequencing was performed successfully in 49 of 60 cases (81.7%), with additional RNA sequencing performed in 20 of 60 cases (33.3%). Recurrent alterations were as expected, including those involving the AR, PTEN, TP53, BRCA2, and SPOP genes. CONCLUSIONS: This prostate cancer bone biopsy protocol ensures a valuable source for high-quality DNA and RNA for tumor sequencing and may be used to detect actionable alterations and resistance mechanisms in patients with bone metastases. Cancer 2018;124:1008-15.
INTRODUCTION
Approximately 90% of patients with metastatic prostate cancer harbor bone metastases, and up to 42.9% of patients have bone-only metastases. 1, 2 With an estimated 26,730 patients expected to die of their disease in 2017 in the United States alone, 3 prostate cancer and associated bone metastases represent a large health burden worldwide. The therapeutic portfolio for patients with metastatic prostate cancer is evolving based on an improved understanding of the molecular framework of metastatic prostate cancer and the identification of potentially actionable targets enriched in advanced disease (eg, homologous recombination genomic alterations and poly [ADP-ribose] polymerase [PARP] inhibitors, mismatch repair/microsatellite instability, and immunotherapy). 4, 5 Biomarker and genomic studies in patients with prostate cancer have been based predominantly on metastatic biopsy protocols embedded within clinical trials and/or developed through consortium efforts at specialized centers, including the Stand Up To Cancer-Prostate Cancer Foundation Dream Teams. [4] [5] [6] Sclerotic bone lesions have been notoriously challenging to biopsy because the amount of tissue obtained is scant and requires decalcification, and often is inadequate for extensive molecular analyses. 7, 8 Using an unguided approach, a previous study demonstrated that only 25.5% of 184 patients with metastatic prostate cancer had a positive bone biopsy. 9 Although success rates for image-guided bone biopsies in specialized academic centers have significantly improved in recent years, the broader application of bone biopsy protocols across the clinical community is challenged by a lack of standardized protocols.
The current study provides a detailed description of a successful next-generation biopsy protocol amenable to sclerotic bone lesions of patients with advanced prostate cancer and broadly applicable to the clinical community. We combined clinical and radiographic features, imageguided percutaneous techniques, and standardized pathology processing protocols to optimize the yield and quality of tissues obtained for downstream testing.
MATERIALS AND METHODS

Patient Cohort
Patients with metastatic prostate cancer were prospectively enrolled on an ongoing precision medicine clinical trial at Weill Cornell Medicine from February 2013 until March 2017 and underwent image-guided bone biopsy by interventional radiology. 10 Institutional review boardapproved written consent was obtained before metastatic biopsy, genomic testing, and clinical follow-up. All lesions were reviewed prospectively by one interventional radiologist (M.H.S.) and were defined as sclerotic, mixed, or lytic via qualitative comparison of attenuation with adjacent areas of intact cortical bone. A schematic figure of the workflow and specimen images can be found in Figure 1 and Figure 2 (see Supporting Information Table 1 ).
Computed Tomography-Guided Bone Biopsy
To identify the shortest path to the bone lesion without intervening vital structures, a biopsy plan was developed based on preprocedure review of standard computed tomography (CT) and bone scan images. The procedure image was reviewed to ensure targeting of metabolic lesions on the nuclear scans, and progressing lesions, if observed, were preferentially biopsied. The plan for each case was to acquire as many core specimens and large blood clots as was safely possible. The shortest path from the skin to the lesion was drawn, attempting to target the periphery of the lesion for the initial cores in sclerotic lesions, or through and through the lesions including the near and far periphery for smaller lesions. Any area was targeted in lytic/mixed lesions. Multiple cores were planned for each case, with the bony yield determining the ultimate number taken. Patients were placed on the CT gantry (Optima CT-580 16 slice wide-bore scanner; GE Healthcare, Little Chalfont, United Kingdom) in supine, prone, or decubitus positions allowing for the selected path and patient comfort. Focal scout images through the target region were performed with 5-mm slices and the patients were prepared in the usual sterile fashion. The skin and periosteum overlying the designated biopsy area were anesthetized with 1% lidocaine (Hospira Inc, Lake Forest, Illinois). Patients received intravenous conscious sedation with midazolam and fentanyl, which was administered and monitored by independent nursing supervision. Biopsies were taken under serial CT guidance (Fig. 3) OnControl system only), and large clots were placed on a nonadherent pad to be frozen. Bleeding back through the large gauge introducer was allowed, with this material used to gather clot as well. Bone biopsies and aspiration samples were handed to the assistant, who immediately placed them on top of wet ice. The biopsy needles were removed and sterile dressings were applied. Postprocedure images were routinely obtained to exclude immediate complications and patients were brought to the recovery area.
Biobanking and Tissue Processing of Bone Biopsies
Bone cores and blood clots were immediately transported on wet ice to the pathology department and tissue was allocated on site for clinical diagnosis, whole-exome sequencing (WES), RNA sequencing, and organoid development ( Fig. 1 ) (see Supporting Information Table 1 ). Tissue was submitted for organoid development only if the concurrent cytology smear was positive for tumor ( Fig. 2) . 11 If it was negative, tissue destined for organoid development instead was frozen for subsequent next-generation sequencing (NGS) if sufficient tumor cells were present at the time of review of frozen slides. Cores were separated into bone marrow and cortical bone specimens. The latter were submitted for clinical diagnosis following standard decalcification. Both bone marrow and blood clots were snap frozen in optimum cutting temperature compound (Tissue-Tek; Sakura Finetek USA Inc, Torrance, California). Frozen sections were cut from the cryomolds and stained with hematoxylin and eosin (H & E). Clinical (ie, cortical bone) and research/precision medicine (ie, frozen bone marrow and blood clots) H & E-stained slides were reviewed by a board-certified pathologist. The frozen H & E slides also were included during the standard-of-care review process. A standard-of-care report was issued for the cortical bone (clinical) specimen. If the clinical specimen was negative for carcinoma, the tissue on the cryomolds was converted into formalin-fixed, paraffin-embedded tissue (FFPE) for clinical purposes. H & E-stained frozen section slides of bone marrow and/or blood clots always were reviewed for tumor adequacy and tumor quantification before sequencing, and compared with the corresponding clinical material (ie, decalcified cortical bone). Both FFPE tissue slides (surgical pathology clinical slides) and frozen section slides (precision medicine clinical trial slides) were scanned at high definition (svs file format) using the Aperio AT2 system (Leica Biosystems, Nussloch, Germany) into e-Slide manager, a password-protected online platform hosted by the Information, Technologies and Service (ITS) department at Weill Cornell Medicine. These images are integrated in the WES report (for a WES/RNA report example and standard operating procedures, see the Supporting Information).
High-density tumor areas were annotated on the H & E-stained glass slide by the pathologist, and tumor cell content was estimated. A published morphologic classification of metastatic prostate cancer was applied to annotate histology. 12 Tumor areas on cryomolds were sampled with a 1.5-mm biopsy punch using the annotated H & E slide as guide. DNA and RNA extraction was performed as previously described. 10 The DNA concentration was measured using the Qubit Fluorometric Quantitation system in ng/lL (ThermoFisher Scientific, Waltham, Massachusetts) and NanoDrop (NanoDrop Technologies, Wilmington, Delaware). 13 NanoDrop also was used for RNA concentration and nucleic acids purity (wavelength absorption at 260/280 nm). Germline DNA from blood or buccal swabs served as the control. 10 Subsequent WES/RNA sequencing and computational analysis were performed as described in detail previously. 10 Our custom computational pipeline includes clonality analysis and sample matching check by CLoNeT (ID Genomics, Seattle, Washington) and single-nucleotide polymorphism panel identification assay, respectively.
14,15
Statistical Analysis
Comparison between groups was performed using the Fisher exact test, Student t test, and one-way analysis of variance. Data collection and analysis was performed with SPSS statistical software (version 24.0; IBM Corporation, Armonk, New York). P values < .05 were considered to be statistically significant.
RESULTS
Demographic and Radiologic Characteristics
The median patient age at time of consent was 71 years (range, 51-92 years). Seventy bone biopsies from 64 patients were performed; of these, 49 biopsies (70%) yielded both bone cores and blood clots simultaneously. Bone biopsies were obtained in 63 of 70 cases and blood clots were acquired in 56 of 70 cases. The number of bone biopsy cores ranged from 1 core up to 8 cores. Blood clots only were obtained in 7 of 70 cases (Table 1, Supporting  Information Table 2 ). Of the 70 bone biopsies, 61 (87.1%) were from sclerotic (blastic) lesions, 8 (11.4%) were from lytic lesions, and 1 lesion (1.4%) was mixed blastic/lytic. Biopsy sites were the iliac bone in 38 of 70 cases (54.3%), lumbar vertebra in 10 cases (14.3%), thoracic vertebra in 7 cases (10%), sacrum in 4 cases (5.7%), and femur in 3 cases (4.3%). Two bone biopsies each (altogether 8.6%) were procured from the pubic bone, rib, and ischial bone, and 1 biopsy each (1.5%) was taken from the sternum and humerus (Table 1 ). In 7 of these biopsies, material was obtained from 2 anatomically distinct sites during the same procedure. In all 7 cases, 1 biopsy was obtained from the iliac bone. The second biopsy was procured from the opposite iliac bone in 3 cases, from the sacrum in 2 cases, and from sternum and lumbar vertebra in 1 case each. All 7 procedures with 2 biopsy sites (total of 14 biopsies) yielded diagnostic material.
In 60 of 70 bone biopsies (85.7%), tissue was procured using the Arrow OnControl Powered Bone Marrow Biopsy System. The Temno Evolution Biopsy Device (18-gauge), the Madison Comprehensive Bone Biopsy System, and the Westcott Fine Needle Aspiration Biopsy (22-gauge) were used in the remaining 5 cases (7.1%), 4 cases (5.7%), and 1 case (1.4%), respectively. No complications (eg, clinically apparent hematoma or infection) were reported. One patient was found to have 2 sclerotic lesions in the right iliac bone. We performed an additional sodium fluoride ( 18 F-NaF) positron emission tomography (PET)-magnetic resonance imaging (MRI) to identify the most metabolic active lesions. 16 Based on the results, the biopsy plan subsequently was adjusted to target L5 vertebra and anterior superior iliac spine (Fig. 4) .
Biopsy Processing and Histopathology
Sixty of 70 tissue samples (85.7%) contained enough tumor tissue to establish a diagnosis, and the other 10 samples (14.3%) were nondiagnostic. Sufficient FFPE tissue was available with which to perform routine immunohistochemistry in 33 of 60 cases (55.0%). Pathology classification of positive biopsies demonstrated that 55 of 60 cases (91.7%) contained usual prostate adenocarcinoma histology (Table 1) . 12 
Metrics for NGS
Tumor tissue was sufficient for sequencing in 49 of the 60 diagnostic cases (81.7%). The tumor content was estimated by histopathology evaluation (data not shown) and by using an algorithm to assess tumor DNA purity and cancer cell ploidy (CLoNeT), 14 and ranged between 10% and 93.9% (mean CLoNeT tumor purity in bone biopsies: 49.6%; mean CLoNeT tumor purity in blood clots: 55.9%). No differences in DNA yield, tumor cell content, coverage, and capture efficiency was observed between anatomic locations. Data regarding the DNA concentration from the bone/blood clot samples were available for 46 of 60 samples (76.7%). The median DNA concentration overall was 25.5 ng/lL (range, 0.53-164.40 ng/lL), was 41.4 ng/lL for DNA from blood clots, and was 32.3 ng/lL for DNA from bone biopsies (P 5 .40). The median 260/280 ratio was 1.81 for DNA and 1.95 for RNA, and thus was sufficient for subsequent NGS. WES, which required a minimum of 225 ng DNA, was successful in 49 of 60 diagnostic cases (81.7%). 10 The mean input was 232.72 ng of DNA for WES and 323.13 ng of RNA for RNA sequencing. WES was successfully performed from blood clots in 26 of 56 cases (46.4%) and from bone biopsies in 23 of 63 cases (36.5%). The mean capture efficiency was 83.6% and the mean coverage was 94.7% (see Supporting Information Table 2 ). Recurrent alterations were as expected in metastatic prostate cancer and included mutation or amplification of the AR gene (4.0% mutation and 32.7% amplification), deletion of PTEN gene (10.2%), mutation or deletion of the TP53 gene (14.3% mutation and 2% deletion), mutation or deletion of BRCA2 (10.2% mutation and 4.0% deletion), and mutation of the SPOP gene (4%). 5 In 37 of 60 diagnostic cases (61.7%), the amount of tissue was insufficient to perform concurrent DNA and RNA extraction, and WES was prioritized. There was enough tissue to also run RNA sequencing in 23 of 60 diagnostic cases (requiring a minimum of 100 ng of RNA), among which it was performed successfully in 20 cases (87.0%). Data regarding the RNA concentration from the bone/blood clot samples were available for 11 samples. The median RNA concentration overall was 16.2 ng/lL. The remaining 3 samples (13.0%) failed RNA sequencing due to poor per base sequence quality (see Supporting Information Table 2 for quality control metrics and additional results). Original Article
DISCUSSION
Patients with advanced prostate cancer commonly harbor sclerotic bone metastases, which are challenging sites to biopsy and the tumor tissue obtained often is limited. We developed a protocol to successfully procure high-quality nucleic acids from metastatic tumors for sequencing, specifically from bone biopsy specimens. We focused on optimizing techniques that limit patient risk by limiting procedure time and radiation exposure and maximizing tissue samples such as the use of blood clots for successful NGS. We also wanted to develop a protocol that did not rely on time-consuming techniques such as laser capture microdissection because these are not always available. Instead, we sampled cryomolds with a biopsy needle using the annotated H & E slide as a guide; this technique resulted in tumor purity that was sufficient for subsequent NGS in the vast majority of cases. Percutaneous bone biopsies have a low complication rate, with a range of 0% to 7.4% reported in the literature. 17 Common complications include muscular hematomas and bleeding and, rarely, biopsy device fracture, nerve injury, and cerebrospinal fluid leak. 18 No complications were noted in the current series, which correlates with other published series using a drill-assisted biopsy system. 19 Fracture of a biopsy device in the thoracic spine has been reported with the use of a 16-gauge Bonopty device (AprioMed, Uppsala, Sweden). 18 In a series of 162 consecutive patients in which the Bonopty device was used, sclerotic lesions were significantly associated with a lower diagnostic yield. 20 This difference was not observed in the current study cohort: 85.2% and 87.7% of sclerotic and lytic lesions, respectively, were found to be diagnostic (P 5 .187). This also is a significantly higher rate of diagnostic biopsies than previously reported for CT-guided biopsies. Table 2 shows a comparison of the current study results with other published studies of bone biopsies in metastatic prostate cancer. 8, [21] [22] [23] In a series of 39 biopsies from patients with metastatic prostate cancer, approximately 77% were found to have at least 1 positive biopsy core. The authors found that a skin-to-bone distance < 6.1 cm was associated with a higher tumor yield on biopsy. 21 In contrast, in the current series, we were able to successfully sequence 88.5% of cases (23 of 26 cases) in which the skin-to-bone distance was 6.1 cm. We observed that the drill-assisted biopsy system improved the diagnostic yield, and thus there was no need to stratify patients further according to published radiologic and clinical criteria for selection because the biopsy was likely to be diagnostic. 22 In 1 patient, additional 18 F-NaF PET-MRI was performed to evaluate 2 lesions in the iliac bone and the biopsy site subsequently was adjusted. 16 PET-MRI has been shown to be more sensitive than PET-CT in detecting bone metastases. 24 It might be a valuable additional tool for identifying those lesions promising the greatest yield of tumor tissue.
To the best of our knowledge, the current study is the first to describe the use of blood clots for NGS, which can be obtained through the drill-assisted biopsy systems. Although cortical bone lesions may have to be decalcified, blood clots can be frozen and further used without additional processing.
Inadequate biopsies may subject the patient to risk without benefit. To our knowledge to date, little has been published assessing the quality of bone biopsies for NGS. One study found a sequencing failure rate of 5 of 21 FFPE bone biopsies, although the reason for this result is uncertain due to a lack of information regarding preanalytical variables such as decalcification. 7 In the current study, the median DNA yield was sufficient for WES (requiring > 225 ng) in the majority of cases and also would have been sufficient for other commonly used targeted gene panels (requiring 10-300 ng). 25 In 7 patients, concurrent biopsies from 2 anatomically distinct sites were performed with an excellent diagnostic yield of 100% and subsequent successful WES in 5 cases (71.4%). Although performing double biopsies increased the procedural time slightly, no complications were noted. This approach could be beneficial to increase the overall amount of tissue. The additional radiation exposure is negligible and could avoid additional biopsy procedures should the initial attempt fails to be diagnostic.
Although liquid biopsies such as circulating tumor DNA are attractive as noninvasive methods for molecular biomarker detection, metastatic tumor biopsies do provide additional information that is not currently well captured by liquid approaches. For example, our approach is to ensure that bone biopsies, and blood clots when available, are handled in a way that allows for morphology assessment and also preserves RNA. Spritzer et al reported a 39% yield for RNA using a 15-gauge Bonopty system. In that study, all 5 iliac bone biopsies in sites other than those adjacent to the sacroiliac joint were insufficient for RNA isolation. 8 In the current study, 6 of 7 sclerotic lesions and 2 of 2 of lytic lesions in such sites were found to be adequate for sequencing.
Conclusions
Historically, the goal of cancer biopsies has aligned with the concept of adequacy, or obtaining just enough sample to allow pathologists to confirm a diagnosis. It now is recognized that antineoplastic treatment changes the molecular landscape of metastatic tumors. 5, 26, 27 Our experience highlights a necessary shift in paradigm in an the era of precision medicine from adequate to sufficient biopsies to address both diagnostic and molecular needs. The results presented in the current study demonstrate that this can be performed safely without significant complications. 
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